Skip to:Content
|
Bottom
Cover image for Targeted interference with signal transduction events
Title:
Targeted interference with signal transduction events
Series:
Recent results in cancer research ; 172
Publication Information:
Berlin : Springer, 2007
ISBN:
9783540312086
General Note:
Also available online version
Added Author:
Electronic Access:
Full Text
DSP_RESTRICTION_NOTE:
Accessible within UTM campus

Available:*

Library
Item Barcode
Call Number
Material Type
Item Category 1
Status
Searching...
30000010150080 RC271.C5 T374 2007 Open Access Book Book
Searching...

On Order

Summary

Summary

Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components? Potential drug targets have been identified, but our ability to predict the consequences of inhibition of such components is still limited. The state of development of tomorrow's cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book.


Table of Contents

Bernd GronerPavan Bendapudi and Pavan Bachireddy and Dean W. FelsherSrinivasan Madhusudan and Trivadi S. GanesanNancy E. HynesYan Wang and Qun-sheng Ji and Mark Mulvihill and Jonathan A. PachterKlaus Podar and Noopur Raje and Kenneth C. AndersonAnne Boulay and Heidi A. Lane and Kathryn Graham and Michael F. OlsonJudith S. Sebolt-Leopold and Roman Herrera and Jeffrey F. OhrenQuan P. Ly and Timothy J. Yeatman
1 Introduction: The Rationale for the Development of Targeted Drugs in Cancer Therapyp. 1
2 Identifying Critical Signaling Molecules for the Treatment of Cancer}}cConstadina Arvanitisp. 5
3 Tyrosine Kinase Inhibitors and Cancer Therapyp. 25
4 Targeting ERBB Receptors in Cancerp. 45
5 Inhibition of the IGF-I Receptor for Treatment of Cancer. Kinase Inhibitors and Monoclonal Antibodies as Alternative Approachesp. 59
6 Inhibition of the TGF-ß Signaling Pathway in Tumor Cellsp. 77
7 The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibitionp. 99 VI8 The R
9 The Mitogen-Activated Protein Kinase Pathway for Molecular-Targeted Cancer Treatmentp. 155
10 Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Eventsp. 169
Go to:Top of Page